Hong Kong Gillian Science

Gilead Sciences is a leading biopharmaceutical company that focuses on the discovery and development of innovative medicines for life-threatening diseases, including HIV, viral hepatitis, and cancer. Headquartered in Foster City, California, the company maintains a significant presence in Hong Kong through its subsidiary, Gilead Sciences Hong Kong Limited. Gilead is renowned for its pioneering work in antiviral therapies, having developed the first single-tablet regimen for HIV and curative treatments for chronic hepatitis C. The company has recently expanded its oncology portfolio through the acquisition of Kite Pharma and Immunomedics, establishing a strong position in cell therapy and antibody-drug conjugates. The name "Hong Kong Gillian Science" is an alternative phonetic transliteration of the company's name frequently encountered in regional patent filings and pharmaceutical databases.